Company intelligence / Profile preview
Tarsus Pharmaceuticals, Inc.
Irvine, California, United Statestarsusrx.com ↗
- Ownership
- Public · TARS
- Employees
- ~323
- Development stage
- Commercial
01
Overview
Tarsus has successfully launched XDEMVY (lotilaner ophthalmic solution, 0.25%), the first and only FDA-approved treatment for Demodex blepharitis. In Q1 2025, they generated $78.3 million in net product sales, an increase of 217% year over year and 18% over Q4 2024[8].
- Therapeutic areas
- OphthalmologyInfectious Diseases
- Modalities
- Small molecules (lotilaner)
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
LianBio (Greater China)Grand Pharmaceutical Group (China)
04
Financials
- Market cap
- $3.3B
- Total revenue
- $451.4M
- Enterprise value
- $3.1B
Beyond the preview
Go deeper on Tarsus Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tarsus Pharmaceuticals, Inc..